About Kailera
Kailera is a company based in Waltham (United States) founded in 2024 by Ron Renaud. Kailera has raised $1 billion across 2 funding rounds from investors including Royalty Pharma, Citadel and Janus Henderson Investors. The company has 4 employees as of April 04, 2024. Kailera offers products and services including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729. Kailera operates in a competitive market with competitors including Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Carmot, among others.
- Headquarter Waltham, United States
- Employees 4 as on 04 Apr, 2024
- Founders Ron Renaud
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Jurisdiction Mumbai, Maharashtra, India
-
Annual Revenue
$705.98 K (USD)11.43as on Mar 31, 2022
-
Net Profit
$29.86 K (USD)154.53as on Mar 31, 2022
-
EBITDA
$66.13 K (USD)340.13as on Mar 31, 2022
-
Total Equity Funding
$1 B (USD)
in 2 rounds
-
Latest Funding Round
$600 M (USD), Series B
Oct 14, 2025
-
Investors
Royalty Pharma
& 13 more
-
Employee Count
4
as on Apr 04, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Kailera
Kailera offers a comprehensive portfolio of products and services, including KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729.
Dual agonist for treating obesity and type 2 diabetes effectively.
Small molecule agonist targeting obesity and diabetes management.
Daily tablet for obesity and diabetes treatment development.
Tri-agonist peptide for obesity and related conditions.
Funding Insights of Kailera
Kailera has successfully raised a total of $1B across 2 strategic funding rounds. The most recent funding activity was a Series B round of $600 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Kailera
Kailera has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Royalty Pharma, Citadel and Janus Henderson Investors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in life science and biotechnology sectors
|
Locked | Locked | Locked | |
|
Investments are focused on pharmaceutical, biotechnology, and medical sectors.
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Kailera
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Kailera
Investment portfolio details for Kailera
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Kailera
Detailed financials for Kailera
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Kailera Comparisons
Peer comparison for Kailera
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Kailera
Kailera operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sana Biotechnology, Semma Therapeutics, Adocia, Rezolute and Carmot, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genetically engineered cell therapies are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment
|
|
| Locked | Locked | Locked |
Therapeutics for diabetes and obesity treatment are developed.
|
|
| Locked | Locked | Locked |
Therapies for metabolic and orphan diseases are developed by Rezolute.
|
|
| Locked | Locked | Locked |
Disease-modifying therapies for metabolic diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of autologous cell therapies
|
Detailed competitors of Kailera
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Kailera
Complete news archive for Kailera
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Kailera
Kailera was founded in 2024.
Kailera is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Ron Renaud is the current CEO of Kailera. They have also founded this company.
Kailera is a funded company, having raised a total of $1B across 2 funding rounds to date.
As of Apr 04, 2024, the latest employee count at Kailera is 4.
Annual revenue of Kailera is $705.98K as on Mar 31, 2022.
Kailera was founded in 2024 and is based in Waltham, United States. Focus is placed on the biotechnology sector, where therapies for obesity and type 2 diabetes are developed. A pipeline of candidates is maintained, including KAI-9531 as an injectable GLP-1GIP receptor dual agonist and KAI-7535 as an oral small molecule. Operations center on advancing these treatments for metabolic conditions.
Kailera's top competitors include Sana Biotechnology, Semma Therapeutics and Adocia.
Kailera offers KAI-9531, KAI-7535, KAI-9531 Oral, and KAI-4729.
Kailera has 14 investors. Key investors include Royalty Pharma, Citadel, Janus Henderson Investors, CPP Investments, and RTW Investments.